Introduction
Much of the current gene therapy research for delivery of genes to the central nervous system (CNS) is focused on developing viral vectors that will give long-term gene expression while causing minimal cytopathology and immunopathology. [1] [2] [3] [4] [5] Experiments designed to evaluate such vectors frequently advance the understanding of biological systems, for example providing useful insight into gene regulation, neuroanatomical tracing 6, 7 and neuroimmunology. 8 Herpes simplex virus (HSV) vectors are attractive as gene therapy vectors because of their neurotropism and their ability to establish a latent infection in the CNS. An HSV vector that has been modified to prevent a lytic infection in the CNS, but which could still enter a latent state would therefore be an attractive candidate for gene delivery. The terminal 1 kb of the long repeat region (RL1) of HSV contains the 'late' ␥34.5 gene, [9] [10] [11] which is required for neurovirulence. Mutants which fail to express ␥34.5 do not replicate in the brain or cause encephalitis following intracerebral inoculation of mice. [12] [13] [14] [15] Lack of ␥34.5 expression does not impair virus replication in tissue culture in several cell types, 16 but replication is restricted in SK-N-SH neuroblastoma cells, 17 murine 10T1/2 cells, stationary phase primary mouse embryo cells 18 and 3T6 cells. 16 In addition, these mutants have been shown to be replication-defective and avirulent in SCID mice, 19 suggesting that their avirulence is an intrinsic property of the virus and is not a result of effective control by the immune system.
The mechanism for the restriction of virus replication in these ␥34.5-viruses is not fully understood. One hypothesis asserts that a failure to express ␥34.5 results in a defect in virus maturation and egress from the nuclei of infected cells. 20 An alternative explanation is that nonpermissive cells infected with such mutants may undergo a total shutoff of protein synthesis, characteristic of an apoptotic state, the function of ␥34.5 being to prevent this response and to allow continued virus replication. 17, 21 Whatever the mechanism of action involved in the restriction of virus growth, ␥34.5 mutants hold promise as potentially suitable vectors for gene transfer to the CNS. 22, 23 In the studies of Coffin et al, 22, 23 in addition to carrying a deletion in the ␥34.5 gene, the E. coli ␤-galactosidase gene was inserted into this variant (1716) under the control of the latency-associated transcripts (LAT) promoter. 23 The rationale for this approach was that the vector might preferentially enter a latent state in the CNS following abortion of the lytic cycle under which conditions the LAT promoter driving E. coli ␤-galactosidase expression would be active.
The purpose of the present study was to investigate further specific aspects of the behaviour of the ␥34.5 mutant, carrying the lacZ insertion, namely (1) to examine specific sites of transgene expression; (2) to correlate this distribution with the expression of viral proteins; and (3) to ascertain whether these findings might be variable within animal strains. The implication of these results with regard to the use of this vector for gene therapy are discussed.
Results

Animal health
When the ␥34.5 deletion mutant 1716 encoding ␤-galactosidase under control of the LAT promoter was inoculated into the right caudate nucleus of AO rats, all animals became ill. They showed abnormal rotational movements by day 2 of the experiment and showed signs of clinical illness such as hunched posture, immobility and ruffled fur by the third day of the experiment. They all showed significant weight loss and developed a severe inflammatory response. 24 Only two PVG rats, out of a series of nine, on the other hand, showed signs of clinical illness.
␤-Galactosidase expression
The vector was inoculated into the right caudate nucleus of AO rats and ␤-galactosidase activity was examined at 12 h and 1, 2, 4, 7, 14 and 32 days. Little or no ␤-galactosidase activity was found at the injection site at any time point. There were, however, ␤-galactosidase-positive cells in a number of secondary sites -sites with known neuronal projections to the caudate nucleus.
25-28 These positive cells were detectable at secondary sites from as early as 12 h and transgene expression reached a peak at these secondary sites at about 2 days declining dramatically by days 4 and 7. No ␤-galactosidase-positive cells were found at times examined thereafter. These observations were consistent between animals and in this experiment a total of five were examined at each time point. When a 10-or 100-fold lower dilution of the virus was inoculated in the same primary site there were no ␤-galactosidase-positive cells in either the primary or secondary sites.
Rostral to the injection site 10 2 -10 3 ␤-galactosidasepositive cells per section were seen distributed bilaterally throughout the cortex, particularly the pre-frontal motor cortex with more positive cells on the ipsilateral side ( Figures 1a, 2a and b) . Caudal to the injection site, 10-10 2 positive cells per section were found in the ipsilateral substantia nigra pars compacta (SNc) and pars reticulata (SNr) and in the ventral tegmental area (VTA) ( Figures  1a, 2c and d) . In the thalamus, 10-10 2 positive cells were seen on the ipsilateral side (in the paracentral thalamic nucleus, the central medial thalamic nucleus and the submedial thalamic nucleus) with occasional positive cells on the contralateral side (Figure 2e and f) . Positive cells were also seen in the locus coeruleus on the ipsilateral side with the occasional positive cell in nuclei on the contralateral side; in the mesencephalic reticular nucleus and in the dorsal raphae (from where serotonin neurons are known to project to the striatum) (Figure 2g ) and the pontine reticular nucleus (Figure 2h) .
PVG rats inoculated with the ␥34.5 deletion mutant 1716 demonstrated a similar pattern of distribution of ␤-galactosidase expression. As in the AO strain there was no ␤-galactosidase expression at the injection site and the peak of expression in all secondary sites was at 2 days as observed with AO rats. The main sites of secondary expression were again those directly linked to the injection site in the caudate especially the pre-frontal motor cortex bilaterally (Figures 1b, 3a and Detection of viral antigens with an anti-HSV polyclonal antibody Brain sections from the same animals as were examined for ␤-galactosidase expression were immunostained at all time points with an anti-HSV polyclonal antibody to ascertain the distribution of expression of viral proteins and to compare the distribution with that of ␤-galactosidase-positive activity. In some cases sections were double stained both for ␤-galactosidase and HSV antigens but in other cases sections were stained to visualise either lacZ expression or viral antigen expression. In AO rats, positive staining with this antibody was found in all areas where there were ␤-galactosidase-positive cells. In addition, there were large numbers of positive cells at the injection site contrasting sharply with the absence of positive ␤-galactosidase cells at this site (Figures 4a and 1a) . Positive staining was seen with this antibody at the primary site from the earliest of time points until 7 days with a peak of expression at about 4 days. By 2 weeks, positive staining was no longer detectable but tissue damage was now evident in the centre of the injection site.
Staining in secondary sites was evident from as early as 12 h in AO rats and the site showing most positive staining at 2 days was the frontal cortex where there were 10 3 -10 4 positive cells per section (Figures 4b, c and 1a, and Table 1 ). Positive staining in the cortex at 2 days was evident in layers 2, 3, 5 and 6 which is consistent with retrograde tracing studies documenting connections of neurons from these layers to the caudate nucleus. Table 1 ). All these areas showed positive staining with ␤-galactosidase at these time points (Figures 1a and 2 ). At the later time points of 4 and 7 days, however, there was still strong positive staining with this antibody in these secondary areas but the staining was now also evident in areas which do not project directly to the caudate nucleus and where ␤-galactosidase activity was never seen. For example, at 4 days 10 3 -10 4 antibody-positive cells were seen bilaterally in the anterior olfactory nuclei (Figures 4g and 1a , and Table 1) , the entorhinal cortex and other parts of the temporal cortex, the hippocampus and amygdala (Figures 4h and 1a, and Table 1 ), areas which do not have neurons projecting to the caudate nucleus. At the later time point of 7 days there was still a significant amount of positive staining with the anti-HSV polyclonal antibody in these tertiary areas but also tissue damage evident particularly in the
Figure 1 Schematic diagram of coronal sections at intervals through the brain caudo-rostrally to illustrate the location of cells stained positive for (A) ␤-galactosidase (b) at 2 days; (B and C) HSV antigen expression (í) at 2 and 4 days following an injection of the ␥34.5 negative virus expressing the lacZ gene (1716) in the caudate nucleus in AO rats (a) and PVG rats (b). (A total of five animals per time-point were examined in the AO series and a total of three at each time-point in the PVG series.) (1) Pre-frontal motor cortex and anterior olfactory nucleus; (2) caudate nucleus (injection site) and motor cortex; (3) thalamus, entorhinal cortex, amygdala and motor cortex; (4) substantia nigra, entorhinal cortex and hippocampus; (5) dorsal raphae, mesencephalic reticular nucleus, and substantia nigra; (6) locus coeruleus. (Note that some areas show HSV antigen expression at 4 days but not at 2 days and ␤-galactosidase expression was never seen in these areas, eg olfactory bulb and all parts of entorhinal cortex.)
Figure 1 Continued.
entorhinal cortex and at the injection site. This tissue damage was still evident at the later time point of 2 weeks and in the limited number of animals examined at 4 weeks.
When PVG rats were examined with this antibody for virus localisation the pattern of distribution was similar to that observed with AO rats. Initially, the greatest amounts of viral antigen could be detected at the injection site and in the major secondary sites of the cortex where there were 10 2 -10 3 positive cells and in the SN where there were less than 10 2 positive cells (Figure 1b) . However, as observed with ␤-galactosidase expression in PVG rats the number of positive cells were an order of magnitude lower than those recorded for AO rats in these sites. At later time-points, viral antigens could be detected in the tertiary sites of the entorhinal cortex and other parts of the temporal cortex (Figure 1b) . In these sites too the expression of viral proteins, detected by the anti-HSV polyclonal antibody, was less intense at all time points compared with AO rats (compare Figures 1a and  b) . Moreover, the tissue damage observed at day 7 was also less widespread.
b) Higher power showing layering of pyramidal neurons mainly in layer 2 (between dotted lines) in the motor cortex. (c) Positive cells in the substantia nigra pars compacta extending into the ventral tegmental area (labelled SNc and VTA, respectively) on the ipsilateral side only. (d) Neuronal profile, in the SNc and VTA (areas between dotted lines), at high power (note absence of non-neuronal cells). (e) Positive cells in different thalamic nuclei: paracentral thalamic nucleus (PCN) central medial thalamic nucleus (CM) and submedial thalamic nucleus (SMT) delineated by dotted lines. Most
Use of a monoclonal antibody to detect de novo viral gene expression Z1F11 is a monoclonal antibody which recognises a 65 kDa DNA binding protein -a product of one of the 'early' genes (UL42) of the virus. Since it is a non-structural protein its presence is indicative of de novo viral gene expression and therefore of progression of the lytic cycle at least as far as 'early' gene expression.
Brain sections which were reacted with X-gal for ␤-galactosidase activity were double stained with this antibody and other sections were stained with this antibody only. Since it is a nuclear protein, positive staining was more punctate than that observed with the anti-HSV polyclonal antibody but the pattern and distribution of staining was, nonetheless, similar to that observed with the polyclonal antibody in most animals. In AO rats positive staining was seen at the injection site where there were positive cells at 12 h and these reached a peak of expression at around 2 days (Figure 4i ). In PVG rats positive staining could also be detected at the injection site at 2 days. Positive staining was also seen with this antibody in all of the secondary sites in both AO and PVG rats where positive staining was observed with the HSV polyclonal antibody. The levels of antigen detected were similar to those described for the polyclonal antibody and there were always substantially more cells positive for both antibodies than for ␤-galactosidase. In doublestained sections, rarely were cells positive for both ␤-galactosidase and this antibody. The peak of expression at secondary sites was about 4 days and significant amounts of protein were still detectable at 7 days. By 4 and 7 days, positive cells were also detectable in the tertiary sites previously described but by 2 weeks, however, no positive cells could be detected.
Discussion
These results show that the neurovirulent mutant of HSV-1, strain 1716, with the lacZ gene under the control 
. There is no staining in the anterior olfactory nucleus (AON) at this time point. (c) High power to show individually stained neurons (arrows). (d ) Positive staining in the substantia nigra pars compacta (SNc) and pars reticulata (SNr) extending to the ventral tegumental area (VTA) on the ipsilateral side. (e) Staining in different thalamic nuclei: paracentral thalamic nucleus (PCN) central medial thalamic nucleus (CM) and submedial thalamic nucleus (SMT) on the ipsilateral side. The third ventricle is labelled V3. (f) Staining in the locus coeruleus on the ipsilateral side and the fourth ventricle is labelled V4. (g) Positive staining in all parts of the anterior olfactory nucleus (AON) on the ipsilateral side at 4 days with no staining in the fibre tracts of the main olfactory bulb (MOB). This contrasts with the AON at 2 days (a) when no staining was found. (h) Positive staining in all layers of the entorhinal cortex (ENT) on the contralateral side and in the CA1 layer of the hippocampus (at 4 days). (i) Positive staining in the injection site with Z1F11, note the punctate nature of nuclear staining and the lack of staining in the white fibre bundle tracts (arrows) which traverse the striatum. The injection tract is depicted by the larger arrow. Scale bar, 600 m (a, b, d, e, g, h); 300 m (f); 150 m (i); 75 m (c).
of the latency promoter results in widespread expression of viral antigen up to 7 days following intracranial inoculation. No reporter gene expression was observed at the injection site and only limited expression was recorded at secondary sites with a peak in expression at 2 days. AO rats became ill in response to inoculation of this viral vector but PVG rats, with few exceptions, remained healthy.
Reporter gene expression was predominantly found in neurons at secondary sites and was restricted to a short time period, up to a maximum of 7 days, following inoculation. The observation that a marker gene may be delivered to and expressed by neurons at a distance from the primary injection site, as a consequence of retrograde neuronal transfer has previously been reported both for herpes virus [29] [30] [31] [32] and adenovirus vectors. [33] [34] [35] [36] The sites of retrograde transport, along known neuranatomical pathways, where the marker gene was expressed showed good correlation between the two rat strains examined. It is not clear why transgene expression became downregulated so quickly at these secondary sites. Since the peak of expression was at 2 days after inoculation of the vector it is questionable whether in fact this expression represents bona fide latency. Another possibility is that the core LAT promoter used in these experiments is unable to drive prolonged reporter gene expression. A recent study on long-term reporter gene expression in the peripheral nervous system of mice has demonstrated that the LAT regulatory sequences downstream of the LAT transcription start site also play a role in facilitating stable gene expression during latency. 37 The most surprising and consistent finding, in the present work, however, was the lack of marker gene expression at the primary injection site in the caudate nucleus. In previous studies with defective HSV viral vectors the most efficient marker gene expression was in the primary site, 29 and in the case of secondary sites a critical titre threshold appeared necessary for marker gene expression to occur at all. 31 In the present work, the cells at the primary site were clearly permissive for viral entry as indicated by the large amounts of viral antigen detected. There are several possible explanations which may account for the lack of reporter gene expression at the primary site. First, it could be a function of the viral vector or its titre. Earlier work has shown that the probability of a lytic outcome following infection of a neuron increases in direct proportion to the number of viral particles that enter the cell. 38, 39 In other words, neuronal latency is promoted by a low multiplicity viral infection. In this case, the vector may have been non-permissive for latency due to the high titre at the injection site. This may relate to the delivery method of using a fine-tipped glass micropipette ensuring a high concentration of the vector at the centre of the injection site. In an experiment designed to test whether a lower virus titre would allow expression of genes under the control of the LAT promoter at the site of injection there was still no expression of ␤-galactosidase when the virus was diluted 10-and 100-fold, in spite of viral gene expression there (results not shown).
Second, the absence of marker gene expression could be a question of neuronal specificity. It is possible that the LAT promoter is not active in any or all classes of striatal neurons in the caudate nucleus. Cellular factors in certain classes of neurons may promote lytic as opposed to latent infection and so allow genes of the lytic cycle to be expressed while genes under the control of the latency promoter are down-regulated. 40 Since the protein sequences of the ␥34.5 gene product show homology with cellular growth arrest genes the presence or absence of such a related gene in an infected cell may result in a differential response of the cells to the virus. 17 In their recent work with this virus Kesari et al 41 found that not only were neurons at the injection site often not LAT+ (as detected by in situ hybridisation) but the level of LAT expression was variable among individual neurons in a given region. They concluded that viral and neuronal factors may act synergistically or independently to determine the expression of LATs which may in turn indicate the selective vulnerability of subsets of CNS neurons to latent infection.
Perhaps the chief and most interesting finding from the results of this work, is the distribution and levels of viral antigen expression following the inoculation of the virus. Viral antigen expression is initially detectable at the earliest time point of 12 h following inoculation of the virus and increases to reach a peak somewhere between 4 and 7 days after injection. This is consistent with the recent findings of Markovitz et al 42 in CBA/J mice where viral antigen expression was also shown to peak at around 5 days following injection of a ␥34.5 mutant into the caudate nucleus. This was found to be the case in both strains of rat examined in the present study. Not only was there an increase in viral antigen, over this time period but the antigen was detectable, at the later times, in sites which have no direct synaptic connections to the injection site in the caudate nucleus. It is difficult to explain this observation without postulating a low level of viral replication. Replication of the virus in glial cells could explain the high levels of viral antigen expression seen at the injection site and associated secondary sites. However, this could not account for the observed antigen expression at the tertiary sites (eg entorhinal cortex and anterior olfactory nucleus), since the only cells expressing viral antigens at secondary sites should be neurons if the virus is non-replicating. The appearance of positive cells at tertiary sites, however, suggests that some low level viral replication at secondary sites has taken place in neurons and perhaps subsequently in local glia in order for trans-synaptic spread to occur. This conclusion is supported by the findings of Markovitz et al 42 that oligodendrocytes and astrocytes were infected at sites distal to the site of injection of this virus, suggesting lowlevel replication.
This conclusion is further supported by findings that infectious virus was recovered from brains up to 4 days following inoculation 24 and that Kesari et al 41 recovered infectious virus for 3 days, following inoculation of this virus, from which they concluded that limited replication occurred during this early time. They also demonstrated the presence of LAT+ cells in these areas at 45 days following an injection in the caudate, further confirming the ability of the virus to spread to these areas.
Although there was good correlation between the two different strains of rat examined in terms of sites of viral and marker gene expression, the levels of expression were higher in AO rats and the PVG rats did not seem to be susceptible to the clinical side-effects suffered by the AO rats. As well as different viral strains 43 and mutants 44 differing in pathogenicity, animal strains also differ in their susceptibility to HSV infection. In studies with mice it has been shown that the nature of HSV infection is somewhat strain-specific, [45] [46] [47] and these results provide evidence of variable responses between the two rat strains studied, although the basis of this difference was not explored. In their recent study which examines differences in resistance to HSV infection in three different strains of mice, Thomas et al 45 hypothesise that the genetically determined innate cellular resistance of glia may play an important role in determining the outcome of HSV-1 CNS infection. Whatever the basis of the differences observed here the higher levels of viral antigen expression are, in any case, probably responsible directly or indirectly for the clinical side-effects. Viral spread in the nervous system can also be determined by the immune status of the animals used 48 and the AO rats are known to be generally high responders immunologically 31 and in this case were not specific pathogen free. The correlation between viral antigen expression and the immune response are described elsewhere. 24 This calls for caution in reaching conclusions about the behaviour of viral vectors based on work carried out in a limited number of animal strains.
Although this viral vector gives significant amounts of transgene expression at early times following intracranial inoculation to be useful for gene therapy, this vector would need to be much more restricted in its growth and spread than observed here. A virus, therefore, that is deleted for other viral genes such as the VP16 transactivating gene, in addition to the neurovirulence gene, might be a more attractive candidate. The product of the VP16 gene is a viral tegument protein on which the expression of the immediate-early genes of the virus are dependent. 49 Additionally, a virus which has the transgene under the control of the LAT promoter cloned into the LAT region in the proximity of the endogenous LAT promoter of the virus might give better long-term gene expression. 50 The need to examine such vectors in more than one animal strain however, also needs to be emphasised.
In summary, while the current generation of gene therapy herpes virus vectors are not ideal for long-term transgene expression in the CNS they do provide important insights into viral behaviour in the brain. Further modifications should make feasible the investigation of neural function and also provide viable vectors for therapeutic purposes.
Materials and methods
Viruses
The virus used in this study was an RL1 deletion variant (1716) of the wild-type HSV strain 17 + , 15 into which the lacZ gene was inserted into the non-essential UL43 gene under the control of the latency-associated transcripts (LAT) promoter. 23 The titre of the virus was 9.8 × 10 8 p.f.u.
Animals
Adult Albino Oxford (AO) rats and piebald viral glaxo (PVG) were used for intracerebral inoculations. All animals were obtained from and housed in the Department of Human Anatomy conventional (non-specific pathogen free) facility.
Surgical procedures
For intracerebral injections rats were anaesthetised with hypnorm and hypnovel. 31 Animals were then placed in a stereotactic injection apparatus and two injections were delivered to the right caudate. The co-ordinates used were bregma, 3.5 mm lateral and 4.5 mm vertical from the dura and 1 mm rostral 3.5 mm lateral and 4.5 mm vertical. A 0.5 l volume of virus (total 5.8 × 10 5 p.f.u.) was used per injection. Injections were made using a fine drawn glass micropipette over a period of a few minutes and the pipette was left in place for an additional few minutes before withdrawal. A minimum of three animals was examined at time points ranging from 12 h to 30 days in the case of AO rats and at days 2, 4 and 7 in the case of PVG rats to measure ␤-galactosidase expression and to determine virus spread using anti-HSV antibodies. Animals were anaesthetised using methoxyfluorane and killed with an intraperitoneal injection of euthatal. They were perfused intracardially using heparinized saline and Zamboni's fixative (1.8% paraformaldehyde and 7.5% saturated picric acid) with 2 mm MgCl 2 and 5 mm EGTA (pH 7.3). Brains were then removed from the animals, post-fixed for several hours and then immersed overnight in 30% sucrose. Finally, they were frozen in Tissue-Tek OCT embedding compound (Miles, IN, USA).
Histochemistry and immunocytochemistry
Seventy-five micron coronal sections were cut on a Leitz 1720 Cryostat (Milton Keynes, UK) and alternate sections collected in phosphate buffered saline (PBS) at 4°C. In each case sections were taken from the olfactory bulb rostrally, through to the brainstem caudally. In some cases sections were stained with 5-bromo-4-chloro-3-indolyl-␤-d-galactoside (X-gal) only, as described previously, 31 to detect ␤-galactosidase-positive cells and in some cases they were reacted with X-gal (3 h at 32°C) and then subsequently double stained with an anti-HSV antibody.
Sections being processed for immunocytochemistry were stained with one of two antibodies: an anti-HSV polyclonal antibody (Dako, High Wycombe, UK) diluted 1:5000 in PBS or Z1F11 mouse monoclonal antibody (a gift from H Marsden, Institute of Virology, Glasgow, UK). This antibody recognises a 65 kDa DNA binding protein of the virus, a product of one of the 'early' genes and was used at 1:1000 in PBS with 1% Triton-X (PBST). Sections were incubated in the primary antibody overnight. Next day after several washes in PBS appropriate HRP-conjugated secondary antibodies were used and the HRP detected with diaminobenzidine (DAB). The incubation time in DAB was 5 min for the anti-HSV polyclonal antibody-treated sections and 10 min for the Z1F11-treated sections. Cells positive for the antigen were visualised as a brown colour in both cases. In the case of the polyclonal antibody staining was somewhat diffuse but with the monoclonal it was much more punctate since the protein being detected is nuclear localised.
Sections were counterstained with either carbol fuschin (or cresyl violet where the sections had not first been stained with X-gal). They were then dehydrated, cleared and mounted.
Analysis
Sections were examined using a Leica WILD MPS52 (Milton Keynes, UK) microscope and scored positive for ␤-galactosidase and/or for viral antigens. When ␤-galactosidase staining was not too heavy it was possible to distinguish individual cells. With the anti-HSV polyclonal antibody the staining was frequently diffuse although the punctate nature of the Z1F11 antibody staining usually made it possible to discern individual cells. However, since it was not always possible to distinguish individual cells, for consistency, estimates of cell numbers were made based on orders of magnitude (10-10 2 , 10 2 -10 3 , 10 3 -10 4 per section). To improve accuracy sections were normally scored by more than one individual.
